Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities

Clinical Oncology

Volumn 23, Issue 9, 2011, Pages 569-571

  Larkin, J M G ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; INTERFERON; IPILIMUMAB;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DRUG COST; EDITORIAL; EXCISION; EXCISION MARGIN; HUMAN; LIMB; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENTINEL LYMPH NODE BIOPSY; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); TRUNK;

HUMANS; LYMPH NODES; MELANOMA; SKIN NEOPLASMS;

EID: 80053386552     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.05.001     Document Type: Editorial

References (9)

1. Wright F., Spithoff K., Easson A., et al. Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk or extremities. Clin Oncol 2011, 23:572-578.
2. Thomas J.M., Newton-Bishop J., A'Hern R., et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004, 350(8):757-766.
3. Long G.V., Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29(10):1239-1246.
4. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355(13):1307-1317.
5. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206.
6. Henderson M.A., Burmeister B., Thompson J.F., et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). J Clin Oncol 2009, 27:18s. (abstract LBA9084).
7. Improving outcomes for people with skin tumours including melanoma 2006, National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence.
8. Marsden J.R., Newton-Bishop J.A., Burrows L., et al. Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg 2010, 63(9):1401-1419.
9. Larkin J., Gore M. Health policy: the UK 'postcode lottery' in renal cell carcinoma. Nat Rev Urol 2009, 6(12):636-638.